GlassScriptPhysician profile
Joseph C Chao
NPI 1992891493
$12,449.63
in general payments reported to CMS, 2019-2025
30 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,373 · 2020: $1,284 · 2021: $2,747 · 2022: $1,908 · 2023: $998 · 2024: $1,778 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,117 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,117.17 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,523.28 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $1,302.31 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $1,281.47 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $993.25 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $830.47 | 2019-2025 | Repatha |
| Arbor Pharmaceuticals, INC. | $790.98 | 2019-2021 | |
| Abbvie INC. | $745.25 | 2019-2024 | |
| Pfizer INC. | $725.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $720.87 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $468.87 | 2021-2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $346.20 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $313.17 | 2022-2023 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $302.27 | 2024-2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $277.49 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals International, Plc | $235.97 | 2024 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $218.78 | 2019 | |
| Boston Scientific Corporation | $174.36 | 2021-2025 | Watchman Flx |
| Ucb, INC. | $173.20 | 2025 | Bimzelx |
| Kowa Pharmaceuticals America, INC. | $172.51 | 2019-2022 | |
| Dermira, INC. | $150.00 | 2019 | |
| Medtronic, INC. | $138.19 | 2022 | |
| Esperion Therapeutics, INC. | $124.99 | 2022 | |
| Janssen Biotech, INC. | $116.02 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $99.73 | 2025 | Nemluvio |
| Amarin Pharma, INC. | $58.92 | 2020 | |
| Azurity Pharmaceuticals, INC. | $58.62 | 2024 | Edarbi |
| Regeneron Pharmaceuticals, INC. | $39.11 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $25.94 | 2019 | |
| Biofrontera INC. | $25.06 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $17.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Chao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.